Evidence map›Paper›PMID 11822990›Full record

ReviewCurrent oncology reports2002

Human papillomavirus in cervical cancer.

F Xavier Bosch, Silvia de Sanjosé

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 111 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. High-Risk Human Papillomavirus (HPV) Infection and Cervical Cancer Prevention in Britain: Evidence of Differential Uptake of Interventions from a Probability Survey.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Specific magnetic isolation for direct detection of HPV16.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012
    Article
  15. Article
  16. Article
  17. Identification of differential expressed transcripts in cervical cancer of Mexican patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011
    Article
  18. Risk of cervical cancer associated with allergies and polymorphisms in genes in the chromosome 5 cytokine cluster.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

F Xavier BoschServei d"Epidemiologia i Registre del Càncer, Institut Català d"Oncologia, Av. Gran Via, s/n. Km 2.7, 08907 L"Hospitalet de Llobregat, Barcelona, Spain. x.bosch@ico.scs.es
Silvia de Sanjosé
Institut Català d'Oncologia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidemiologic studies supported by molecular technology have provided sufficient evidence of the causal role of some human papillomavirus (HPV) infections in the development of cervical cancer. The finding is consistent universally, and HPV has been proposed as the first identified necessary cause of cervical cancer. Such recognition translates into the concept that cervical cancer does not develop without persistent presence of HPV DNA. In the developed parts of the world, cytologic screening programs could benefit from the addition of HPV testing to their protocols. Controlled studies and one randomized trial have shown that HPV testing is helpful in solving the ambiguous cases generated by cytology reading. In populations where cytology programs are not functional or efficient, HPV testing is being evaluated as an alternative means of primary screening. Prevention of exposure to high-risk HPV types, either by prophylactic vaccination or by combined prophylactic and therapeutic immunologic intervention, may prove to be the most efficient and logistically feasible option for the prevention of cervical cancer in developing populations.

Indexed as

PapillomaviridaeAge DistributionAge FactorsFemaleHumansMass ScreeningPapillomavirus InfectionsPrevalenceTumor Virus InfectionsUterine Cervical NeoplasmsVaginal SmearsViral VaccinesViral Vaccines

Identifiers

PMID11822990
OpenAlexW2071854592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.